More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

JP Morgan Healthcare Conference

Jan 10, 2023 at 1:44 AM EST · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Jan 10, 2023 at 1:44 AM EST

On 6ix: 6ix.com/news/jp-morgan-healthcare-conference

Recce Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

  • Australian Patent to be Granted for RECCE Anti-InfectivesJan 9, 2023
  • Anti-Infective Research Unit est. at Murdoch ChildrensDec 15, 2022
  • Approval to Start Phase I/II Diabetic Foot Ulcer StudyDec 8, 2022
  • Anti-Infective Portfolio Update and Webinar detailsOct 18, 2022
  • Pause in tradingOct 17, 2022

Later from Recce Pharmaceuticals

  • A$6.21m Received from R&D Rebate PaymentsJan 24, 2023
  • Recce Selects CMAX for Phase I/II UTI Clinical TrialFeb 19, 2023
  • Corporate Presentation - WI Emergence 2023Mar 22, 2023
  • Recce Receives Further A$973,144 R&D AdvanceApr 4, 2023
  • New Family 4 Patent to be Granted for RECCE Anti-InfectivesApr 10, 2023
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer